TY - JOUR
AR - COR-2020-12-104
TI - Impact of Immune Checkpoint Inhibitor on the Survival in Elderly Patients with Non-Small Cell Lung Cancer
AU - Minehiko, Inomata
AU - Kenji , Azechi
AU - Naoki , Takata
AU - Kana , Hayashi
AU - Kotaro , Tokui
AU - Chihiro , Taka
AU - Seisuke , Okazawa
AU - Kenta , Kambara
AU - Shingo , Imanishi
AU - Toshiro , Miwa
AU - Ryuji , Hayashi
AU - Shoko , Matsui
AU - Kazuyuki , Tobe
JO - Clinical Oncology and Research
PY - 2020
DA - Thu 31, Dec 2020
SN - 2613-4942
DO - http://dx.doi.org/10.31487/j.COR.2020.12.04
UR - https://www.sciencerepository.org/impact-of-immune-checkpoint-inhibitor-on-the-survival-in-elderly_COR-2020-12-104 
KW -  Elderly, immune checkpoint inhibitor, lung cancer
AB - Purpose: We analysed the relationship between a history of immune checkpoint inhibitor (ICI) and overall
survival in elderly patients with non-small cell lung cancer (NSCLC).
Methods: We conducted a retrospective analysis of the data of patients with NSCLC aged ≥70-year-old
who had received systemic anticancer therapy between 2015 and 2019.
Results: The analysis included the data of a total of 63 patients. Multivariate analysis revealed a significant
association between a history of treatment with ICI and the overall survival. A significant interaction was
also observed between a history of treatment with an ICI and the tumor histology.
Conclusion: A significant association between history of ICI therapy and the overall survival was detected
in elderly NSCLC patients aged ≥70-year-old in a clinical practice setting. Our results also suggested that
the impact of ICI therapy on the survival differed depending on the tumor histology.